e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Therapy of thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients
J. Skrickova, M. Tomiskova, I. Vasutova, B. Kadlec, J. Kaplanova, L. Babickova, P. Turcani, T. Nebesky, L. Kren, L. Buresova (Brno, Czech Republic)
Source:
Annual Congress 2008 - Therapy of thoracic tumours
Session:
Therapy of thoracic tumours
Session type:
E-Communication Session
Number:
4302
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Skrickova, M. Tomiskova, I. Vasutova, B. Kadlec, J. Kaplanova, L. Babickova, P. Turcani, T. Nebesky, L. Kren, L. Buresova (Brno, Czech Republic). Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients. Eur Respir J 2008; 32: Suppl. 52, 4302
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 672s
Year: 2004
Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC)
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019
Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue
Source: Annual Congress 2010 - The role of biomarkers in lung cancer
Year: 2010
Tobacco exposure and survival in non small cell lung cancer patients treated with erlotinib
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002
Main reasons for a low accrual pattern in clinical trials of patients with advanced stage non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Influence of teaching models on skills and knowledge of medical doctors
Year: 2008
A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Characteristics and prognostic relevance of
p
53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation
Source: Annual Congress 2011 - Quality management for lung cancer patients
Year: 2011
A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study
Source: Eur Respir J 2007; 29: 128-133
Year: 2007
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Compassionate-use gefitinib in non–small cell lung cancer (NSCLC): results from a US expanded access program (EAP)
Source: Eur Respir J 2004; 24: Suppl. 48, 231s
Year: 2004
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept